NJ-LABVANTAGE
22.2.2024 13:31:32 CET | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, has made available its semantic search (AILANI), advanced analytics, and LIMS solutions in an integrated, digitally native ecosystem capable of seamlessly supporting R&D laboratory processes. This ecosystem will enable R&D labs to improve efficiency, productivity, decision-making, collaboration, and ultimately time-to-market while reducing operational cost. LabVantage will present its LIMS solutions and integrated ecosystem at Pittcon 2024 (Booth #2133), February 24-28, in San Diego, California.
Digitizing R&D laboratory processes with advanced technologies such as semantic search, analytics, and LIMS marks a significant leap towards efficiency and innovation in the scientific domain. Semantic search capabilities enable the contextualization and searchability of vast amounts of data and documents, utilizing a semantic core and knowledge graph. This technology not only streamlines information retrieval and drastically reduces repetition in experimental runs, but also enhances the decision-making process by providing more relevant and precise data insights. Some LabVantage customers have experienced a 30% reduction in repeated experiments by implementing LabVantage’s semantic search tool, AILANI.
Integrating AI and Business Intelligence into a unified analytics platform, in tandem with LIMS, accelerates analysis and reporting. LabVantage Analytics provides analysis of both structured and unstructured data from diverse sources, integrating data processing, storage, analysis, and visualization in one platform. Its user-friendly self-service features include customizable dashboards and immediate access to LIMS data reports.
“By incorporating advanced technologies like semantic search, AI, and analytics into our LIMS solutions, we're not only enhancing data precision and reducing experimental repetition but also driving significant improvements in collaboration and experiment design. Together, these tools will be instrumental in enabling customers to design better experiments while drastically reducing the total number of experimental runs,” said Alan Marcus, Chief Growth Officer at LabVantage Solutions. “Our goal is to hand back more time to customers for scientific exploration. In fact, we believe these digitally native solutions will expand our ability to serve clients in all supported industries throughout their entire product lifecycle. Your data can now be unified, housed, searched, and analyzed within a single platform from concept to market.”
The implementation of a LIMS automates and manages laboratory workflows, significantly boosting efficiency and consistency in experiment execution. By integrating with search and analytics tools, LabVantage LIMS ensures a seamless flow of information, further elevating laboratory operations, decision-making, and collaboration. Industry statistics underscore the transformative impact of such digitization and automation with laboratories reporting up to a 30-40% increase in productivity.1
LabVantage’s merger with Biomax Informatics has enhanced its analytics and LIMS solutions by integrating AILANI, an advanced semantic search tool. AILANI synergizes semantic modeling, ontologies, linguistics, and AI algorithms to revolutionize query-based research. This tool effectively connects various data sources—internal, external, and proprietary—empowering researchers to swiftly discover valuable insights and hidden patterns. It also simplifies and accelerates decision-making throughout the R&D process by offering easy access to relevant information and its context.
LabVantage Biomax was recognized in the Gartner® Hype Cycle™ for Life Science Discovery Research 2023 as a Sample Vendor for two categories: ‘Semantic Knowledge Graph Tools’ and ‘Analytics Platforms for Research Informatics’.2 Similarly, LabVantage was ranked as a top growth and innovation leader in 2023 by Frost & Sullivan in the firm’s first annual global life sciences LIMS report and radar, highlighting LabVantage's commitment and status as a pivotal player in transforming life science research and analytics.
For more information on LabVantage, its LIMS solutions, and digitally native R&D ecosystem, visit www.labvantage.com or email info@labvantage.com.
References:
- McKinsey & Company. Digitization, Automation, and Online Testing: The Future of Pharma Quality Control. McKinsey & Company Life Sciences.
-
Harwood, R. Gartner® Hype Cycle™ for Life Science Discovery Research, 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222841525/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering11.5.2026 21:49:00 CEST | Press release
INNIO Group ("INNIO"), a leading global distributed energy solutions provider, today announces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511389675/en/ INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. INNIO has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays and Citigroup are acting as book-running managers for the proposed offering. Baird, BNP Paribas
Only 7% of Companies Achieve Full Compliance as Global Expansion Increases Legal Complexity11.5.2026 15:00:00 CEST | Press release
47% of general counsels say beneficial ownership rules pose the biggest risks to legal operations44% lack confidence in meeting cross-border data security requirements As businesses accelerate their global expansion in 2026, compliance fails to keep pace. In fact, only 7% of organizations report full compliance across their global entities, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 350 general counsel (GCs) and senior legal professionals across Europe, North America, and Asia Pacific to examine how their teams navigate international expansion, regulatory pressure, and the increasing adoption of artificial intelligence (AI).¹ The findings appear in CSC’s latest report, General Counsel Barometer 2026: From Complexity to Control. Most organizations report partial compliance, with over half (53%) estimating they are 50–75% compliant, and a further 35% placing themselves between 76%–99%. This leaves just 7%
IFF Opens Vanilla Innovation Center in Madagascar11.5.2026 14:15:00 CEST | Press release
Advancing science‑led flavor innovation where vanilla is grown IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health & bioscience—today announced the opening of its Vanilla Innovation Center in Madagascar, reinforcing vanilla as a strategic and priority tonality for IFF and strengthening its ability to innovate at origin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508110162/en/ IFF's Vanilla Innovation Center in Madagascar “The opening of the center marks an important step in how we approach vanilla innovation,” said Adam Jańczuk, Ph.D., senior vice president, research, creation and design, Taste, IFF. “By strengthening our presence at origin, we connect science, creativity and sustainability more closely, responding to climate changes, safeguarding quality and creating value across the supply chain.” Located in Toamasina, Madagascar’s principal seaport, near vanilla growing areas and post‑h
ARIS Recognised as a Leader in Gartner® Magic Quadrant™ for Process Intelligence Platforms, Believes This Reinforces Its Role in Enabling Enterprise AI at Scale11.5.2026 14:00:00 CEST | Press release
ARIS, the process context foundation platform for enterprise AI deployment, today announced its recognition as a Leader in the Gartner® Magic Quadrant™ for Process Intelligence Platforms. This is the fourth consecutive year that ARIS has been recognized as a Leader in the report and the company believes it underscores a continued commitment to innovation and growth as enterprises focus on turning AI ambition into measurable business outcomes. While technology has advanced rapidly, companies are struggling to operationalise AI across complex operating models. ARIS sees this recognition by Gartner as a reflection of its strength in delivering a single unified platform for process intelligence, providing the context layer on which G2000 organisations can successfully deploy and scale agentic AI. “AI is moving from experimentation to execution – but many enterprises are finding it difficult to scale,” said Guillaume Bacuvier, CEO of ARIS. “The reason is simple: AI lacks the context it need
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors11.5.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking authorization to expand the use of its Edison® Histotripsy System to include the destruction of kidney (renal) tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511268688/en/ HistoSonics Edison® Histotripsy System This milestone marks a significant step forward in the company’s mission to transform the treatment of solid tumors with a completely non-invasive technology that harnesses focused ultrasound to mechanically liquefy and destroy targeted tissue, reducing the risk of many complications and side effects associated with surgery, radiation, and other common therapies. “This submission is an important milestone in expanding histotripsy beyond the liver and into the kidney, an area where patients and physicians are s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom